1. Klein P, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015 Dec;56(12):1890-98.
  2. Sehn LH, et al. GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma (abstract LBA8502). Presented at 2015 ASCO Annual Meeting. May 29-June 2, 2015. Chicago, IL.
  3. Yao JC, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2015 Dec 15.
  4. Turner NC, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015 Jul 16;373(3):209-19.
  5. Poordad F, et al. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology. 2016 Jan 11.
  6. Wyles DL, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015 Aug 20;373(8):714-25.
  7. A special meeting review edition: Advances in the treatment of hepatitis C virus infection from EASL 2015. Gastroenterol Hepatol (N Y). 2015 Jun; 11(6 Suppl 3): 1–23.
  8. Prilosec (omeprazole) prescribing information. AstraZeneca, LP. Wilmington, DE. February 2016.
  9. Complera (emtricitabine/rilpivirine/tenofovir DF) prescribing information. Gilead Sciences, Inc. Foster City, CA. February 2016.

Contributor Information


Mary L Windle, PharmD
Editor-in-Chief, Medscape Drug Reference


  • Google+
  • LinkedIn